Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma. From January 1992 to January 1995, 27 children (15 male, 12 female) with relapsed or refractory evaluable osteosarcoma were included in a phase II study of two courses of ifosfamide 3g/m2/day and etoposide 75 mg/m2/day for 4 days. Median age was 14 years (7-19 years). All but one had received high-dose methotrexate and doxorubicin as first-line treatment. 22 patients had previously received ifosfamide. This regimen was given as first-line in 1 patient, second-line in 23 and third-line in 3. Evaluable disease was lung metastases in 21 patients, local relapse in 5 and adenopathy in 1. There were six complete responses, seven partial responses, three minor responses, six stable disease and five progressive disease (including one mixed response). Response rate was 48% (95% confidence interval, 29-67%). Duration of response was not available (10 responding patients had other treatments). Response rate was equivalent in the subgroup of 22 patients who had previously received ifosfamide (4 CR, 6 PR). Among 3 patients who received the phase II regimen as third-line chemotherapy, there was 1 PR. All but 4 patients had a well tolerated grade 4 neutropenia. Transient mild confusion or seizures were each observed once. 5 patients are alive 15-31 months after the beginning of chemotherapy. This combination of drugs at this dosage has tolerable toxicity, is efficient and deserves evaluation in phase III studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since the 1990s, the combination of IE has been employed in multiple pediatric clinical settings, with a phase II trial reporting a response rate of 48% and acceptable toxicity in relapsed or refractory pediatric osteogenic sarcomas10.”
In the citing paper
“Additionally, PFS data for IE in relapsed or refractory osteosarcoma were published several decades before the OLIE study46; thus, the PFS estimate for IE relied on limited historical data from other clinically active agents,15,35,36 and IE performed better than expected relative to these assumptions.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [46]
In the citing paper
“These chemotherapy regimens are recommended based on phase II trials or retrospective studies with small numbers of patients with osteosarcoma showing moderate response rates of 20-50% 142,143,144 .”
From Osteosarcoma (2022) · cites this paper as [142]
Citations
Cites
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Gehan, E. A. (1961) · Journal of Chronic Diseases · doi:10.1016/0021-9681(61)90060-1 · Cited by 667
Winkler, K., Beron, G., Delling, G., Heise, U., Kabisch, H., Purfürst, C., Berger, J., Ritter, J., Jürgens, H., & Gerein, V (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.329 · Cited by 459
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317
Kung, F. H., Pratt, C. B., Vega, R. A., Jaffe, N., Strother, D., Schwenn, M., Nitschke, R., Homans, A. C., Holbrook, C. T., Golembe, B., et al. (1993) · Cancer · doi:10.1002/1097-0142(19930301)71:5<1898::aid-cncr2820710529>3.0.co;2-q · Cited by 110
Harris, M. B., Cantor, A. B., Goorin, A. M., Shochat, S. J., Ayala, A. G., Ferguson, W. S., Holbrook, T., & Link, M. P. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950240205 · Cited by 110
Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid Tumours
European Organization for Research on the Treatment of Cancer, C. S. G. (1973) · BMJ · doi:10.1136/bmj.3.5873.199 · Cited by 106
High-dose ifosfamide in advanced osteosarcoma.
Marti, C., Kröner, P. T., Remagen, W., Berchtold, W., Cserhati, M., & Varini, M. (1985) · PubMed · Cited by 89
Pyogenic cocci in infantile eczema throughout one year.
Smith, R., Alder, V. G., & Warin, R. P. (1975) · BMJ · doi:10.1136/bmj.3.5977.199 · Cited by 87
Nissen, N. I., Pajak, T. F., Leone, L. A., Bloomfield, C. D., Kennedy, B. J., Ellison, R. R., Silver, R. T., Weiss, R. B., Cuttner, J., Falkson, G., et al. (1980) · Cancer · doi:10.1002/1097-0142(19800115)45:2<232::aid-cncr2820450206>3.0.co;2-f · Cited by 69
Research works printed but not linked: 2
- Pratt, 1987, Phase II trial of ifosfamide in children with malignant tumors, Cancer Treat Rep, 71, 131
- Miser, 1987, Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults, J Clin Oncol, 5, 1191, 10.1200/jco.1987.5.8.1191 · DOI · Paper page
Cited by
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Whelan, J. S., Bielack, S. S., Marina, N., Smeland, S., Jovic, G., Hook, J. M., Krailo, M., Anninga, J., Butterfass-Bahloul, T., Böhling, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu526 · Cited by 333
“[9, 20-22] These important questions were amenable to a relatively simple trial design.”
BackgroundCurrent Treatment of Osteosarcoma
Ferguson, W. S., & Goorin, A. M. (2001) · Cancer Investigation · doi:10.1081/cnv-100102557 · Cited by 295
Mialou, V., Philip, T., Kalifa, C., Perol, D., Gentet, J., Marec‐Berard, P., Pacquement, H., Chastagner, P., Defaschelles, A., & Hartmann, O. (2005) · Cancer · doi:10.1002/cncr.21263 · Cited by 286
“with known effectiveness against osteosarcoma, such as high-dose methotrexate,(9) doxorubicin,(10) cisplatinum,(11) etoposide, and high-dose ifosfamide.(12) Twenty-two patients were treated according to the French Society of Pediatric Oncology (SFOP) OS 87 protocol,(13) 39 patients were treated according to the OS 94…”
Self-citationNew targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Metadata
- Authors
- Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., Pillon, P., Bernard, J. L., & Kalifa, C.
- Affiliations
- Centre Léon Bérard (FR)
- Centre Oscar Lambret (FR)
- Institut Gustave Roussy (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Institut Curie (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Queen Fabiola Children's University Hospital (BE)
- Corresponding author
- Gentet, J.-C.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 1997-02
- Volume
- 33
- Issue
- 2
- Pages
- 232-237
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2018217408
- Cited by
- 86
- References
- 15
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 2 · 2020: 8 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 3
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- European Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- ifosfamide, etoposide, high-dose chemotherapy, second-line chemotherapy, lung metastasis, neutropenia, chemotherapy toxicity, treatment response rate
- MeSH terms
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Child, Etoposide, Female, Humans, Ifosfamide, Male, Osteosarcoma, Survival Rate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology. https://app.cochat.ai/papers/10.1016/s0959-8049(96)00439-x
- The paper
- Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., Pillon, P., Bernard, J. L., & Kalifa, C. (1997). Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the french society of paediatric oncology. European Journal of Cancer. https://doi.org/10.1016/s0959-8049(96)00439-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.